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Psychomotor depressive symptoms may differentially
respond to venlafaxine
Ajeet B. Singha,b, Chad A. Bousmanb,c,f,d, Chee H. Ngb, Keith Byrong
and Michael Berka,b,d,e
Predicting differential antidepressant efficacy remains
an elusive goal in major depressive disorder (MDD).
The aims of this study were three-fold. Firstly, to examine if
psychomotor retardation symptoms (item 8 on the 17-item
Hamilton Depression Rating Scale) improve preferentially
to venlafaxine (VEN) over escitalopram (ESC) treatment.
Secondly, whether the 18 item CORE psychomotor signs
scale predicted antidepressant remission. Finally, to
investigate the role of two norepinephrine transporter
gene (NET) polymorphisms (rs2242446 and rs5569) on
antidepressant efficacy. Adults with Diagnostic and
Statistical Manual of Mental Disorders, 4th ed. MDD
(n=113) were treated with ESC or VEN prospectively for
8 weeks and rated serially with the Hamilton Depression
Rating Scale. In a subsample (n=51) of patients from
one of the three recruitment sites, the CORE psychomotor
signs scale was also administered at baseline. Participants
treated with VEN had significantly greater reduction
in psychomotor retardation symptoms than those treated
with ESC. The CORE scale did not predict antidepressant
response or remission. Neither NET polymorphism
moderated antidepressant efficacy. Findings suggest
possible preferential utility of a selective serotonin
and noradrenaline reuptake inhibitor in cases of MDD
presenting with greater psychomotor retardation.
The moderate to small sample size makes a type II
error risk possible, and the negative findings need to be
interpreted with caution. The positive finding of preferential
efficacy of VEN for psychomotor retardation symptoms
has potential translational utility. Int Clin Psychopharmacol
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Introduction
Noradrenaline appears to have various important roles in
the central nervous system, particularly in mediating
arousal states (Ressler and Nemeroff, 1999). Multiple
lines of evidence suggested that the noradrenergic system
is disordered in major depressive disorder (MDD) (Potter
et al., 1993; Schatzberg and Schildkraut, 1995; Heninger
et al., 1996; Leonard, 1997; Owens et al., 1997; Owens,
1997; Charney, 1998). Noradrenergic dysfunction in
MDD may produce a subset of depressive symptoms.
Reduced noradrenergic activity may contribute to de-
creased concentration, mental and physical slowing, poor
energy, tiredness, and reduced self-care (Nutt, 2008).
These symptoms may be particularly impairing in work
and social settings (Tse and Bond, 2002). Other studies
have suggested that noradrenaline reuptake inhibitors
preferentially treat social drive and functioning better
than selective serotonin reuptake inhibitors (SSRIs)
(Dubini et al., 1997; Massana et al., 1999).
Item 8 of the Hamilton Depression Rating Scale (HDRS)
examines slowness of thought and speech, impaired
ability to concentrate, and decreased motor activity, and
rates it on a 0–4 scale. A subanalysis of data from a study
comparing the selective serotonin and noradrenaline
reuptake inhibitor (SNRI) milnacipran with the SSRI
paroxetine (Kasper, 1997) found item 8 of the HDRS
preferentially improved with milnacipran. In a study of
182 patients with Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. (DSM-IV)-defined MDD, participants
were assessed at baseline and 12 months after naturalistic
clinical care (Parker et al., 2001). The CORE scale
measures 18 psychomotor signs (noninteractiveness,
retardation, and agitation subscales), which are rated
(score 0–3) at the end of a clinical interview (Parker and
Hadzi-Pavlovic, 1996; Joyce et al., 2002). Higher CORE
scale scores were associated with better response to
electroconvulsive therapy, tricyclic antidepressants, and
the irreversible monoamine oxidase inhibitors compared
to other treatments such as SSRIs and psychotherapy
(Parker and Hadzi-Pavlovic, 1996; Parker et al., 1999;
Parker et al., 2001). But it is unclear whether the wider
psychomotor signs captured in the CORE scale
has greater antidepressant response predictive utility
than baseline HDRS severity alone (Fournier et al.,
2009; Fournier et al., 2010).
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The norepinephrine transporter (NET) is a sodium-
dependent transporter, which reuptakes norepinephrine
into the neuron for both cyclic use and termination of the
action of norepinephrine at the synapse (Amara and
Kuhar, 1993; Uhl and Johnson, 1994; Be´ı¨que et al., 1998).
Several studies have examined the role of NET poly-
morphisms in mood and related disorders with no
statistically significant associations found (Owen et al.,
1999; Leszczynska-Rodziewicz et al., 2002; Samochowiec
et al., 2002; Zill et al., 2002; Chang et al., 2007; Dong et al.,
2009; Min et al., 2009; Uher et al., 2009; Baffa et al., 2010).
This is counter balanced by positive associations in other
studies suggesting NET rs2242446 and NET rs5569 single
nucleotide polymorphisms (SNPs) may predict preferential
response to noradrenergic over serotonergic antidepressants
in MDD (Higuchi et al., 2003; Ryu et al., 2004; Yoshida et al.,
2004; Kim et al., 2006; Baffa et al., 2010). These associations
are mechanistically plausible given the rs2242446 poly-
morphism is located in the NET promoter region and
appears to alter transcription (Zill et al., 2002). In addition,
the synonymous rs5569 polymorphism in exon 6 has been
linked to alternative mRNA splicing and reduced NET
functioning (Sogawa et al., 2010), and has been associated
with preferential response to noradrenergic antidepressants
(Kim et al., 2006).
The aims of this study were to explore both clinical and
genetic moderating factors of antidepressant efficacy. The
primary aim was to examine whether psychomotor retarda-
tion symptoms (item 8 on HDRS) improve preferentially
to the SNRI venlafaxine (VEN) over the SSRI escitalopram
(ESC). The secondary aim was to examine whether the
CORE scale at baseline predicted antidepressant remission
controlled for baseline HDRS score severity. The tertiary
aim was to examine whether two NET polymorphisms
(rs2242446 and rs5569) predict differential antidepressant
efficacy between VEN and ESC.
Materials and methods
There were three recruitment sites – two in Australia
(Melbourne and Geelong) and one in Singapore. Partici-
pants were either of Caucasian (European Australian) or
Asian (Han Chinese, Singaporean) backgrounds. Patients
18 years and over with a principal diagnosis of MDD
(DSM-IV criteria, assessed by semistructured clinical
interview) were studied. A body of evidence suggests that
more severe episodes of MDD have better response rates
to antidepressants than milder cases (Sotsky et al.,
1991; Paykel et al., 1988; Khan et al., 2005; Fournier
et al., 2010), thus a HDRS score of at least 18 was
required to exclude milder cases of MDD, which may be
less medication responsive. Patients who had treatment
refractory depression (Z 3 failed medication trials) were
excluded. Patients were studied prospectively for 8 weeks
with HDRS ratings as the primary outcome measure.
Antidepressant response was defined as at least 50%
reduction in HDRS from baseline (Zajecka, 2003;
Moncrieff and Kirsch, 2005). Clinical Global Impression
scales for improvement and severity were used to guide
clinical dose adjustment (Berk et al., 2008). A subgroup of
participants from one of the recruitment sites (Geelong)
had baseline CORE scale data collected (Parker and
Hadzi-Pavlovic, 1996). Ratings were blinded to genotype.
Before commencement there was a drug washout period
(five half-lives of the previous agent) for participants
already receiving an antidepressant. During the first week
all patients received a standard dose of either ESC 10 mg/
day or VEN 75 mg/day. Drug selection was based on
patient’s preference of side-effect profile. At weeks 1, 4,
and 8 of treatment doses were adjusted on a clinical basis,
with the dose escalated if there was no improvement on
the Clinical Global Impression Scale, or the dose reduced
if problematic side effects emerged [elevation of the
UKU side effects scale (Lingjaerde et al., 1987) with
patient intolerance reported]. No other psychotropic
medications were given and psychotherapy was not
commenced during the study period. Two candidate
NET SNPs (rs2242446 and rs5569) were genotyped.
In addition, genotyping of CYP2D6 and CYP2C19 poly-
morphisms was conducted to control for metabolized
status, and 5HTTLPR genotype was also assayed as
potential antidepressant efficacy confounders (Porcelli
et al., 2011; Singh et al., 2012). The study was approved by
the relevant research ethics committees (Study 138, The
Melbourne Clinic, Richmond, Australia; and Changi
Hospital, Singapore).
Genotyping
DNA was extracted from each sample using QIAamp
DNA Mini Kit (Qiagen Inc., Chadstone, Victoria,
Australia) from venous blood or buccal brush samples.
Genotypes of candidate (NET rs2242446 and rs5569) and
potential confounding (CYP2D6 and CYP2C19 metabo-
lizer status, and 5HTTLPPR s and l genotype) (Porcelli
et al., 2011) were determined by the PCR followed by
single primer extension and analysis on a Sequenom
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry 384-well genetic analysis system.
Statistical analysis
Data were analyzed using SPSS (version 19; SPSS Inc.,
Chicago, Illinois, USA). Differences in categorical and
continuous demographic data by treatment received
(ESC or VEN) were examined using w2 and t-tests,
respectively. For the primary analysis, intention-to-treat
analysis was applied. Repeated-measures analysis of
variance was used to determine changes in HDRS item
8 by antidepressant type. Logistic regression was used to
estimate the odds of responding to ESC or VEN based on
HDRS item 8 and CORE baseline scores. To examine
whether either of the two NET polymorphisms moder-
ated treatment efficacy, interaction terms were created
(e.g. HDRSNET and CORENET) and included in
the regression models. The CubeX program was applied
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to detect departures from Hardy–Weinberg Equilibrium
(HWE) and estimate pairwise linkage disequilibrium
(LD) measures r2 and D0 (Gaunt et al., 2007). Poly-
morphisms with HWE greater than 0.01 were considered
to be in equilibrium. LD was assumed if a pair of SNPs
had r2 and D0 values greater than 0.80 with haplotype
analysis performed if LD existed.
Results
Of 113 participants enrolled in the study, 98 had
sufficient data to determine antidepressant efficacy.
At baseline, six participants had a HDRS less than 18
so were excluded from the analysis, two participants
withdrew consent before assessment, and seven partici-
pants withdrew before either week 4 or 8 HDRS rating –
preventing determination of medication efficacy.
A subgroup of participants had baseline CORE scale
administered (n= 51). Table 1 displays the baseline
features of participants included in the analysis (n= 98)
of differential antidepressant efficacy for psychomotor
retardation (item 8 of the HDRS) stratified by medica-
tion. No confounders were noted among clinical, demo-
graphic, and genetic characteristics (Table 1). The
rs2242226 and rs5569 NET polymorphisms did not differ
by treatment group, were in HWE (P> 0.10), and were
not in LD (D0 = 0.13, r2 = 0.02). Thus, haplotype analysis
was not necessary.
Treatment effects on psychomotor symptom reduction
The response rate by antidepressant was not significantly
different, with the VEN response rate 63.4% and the ESC
response rate 73.7% (z= 1.07, P= 0.284). Participants
receiving VEN had significantly greater reductions in
psychomotor retardation (item 8 HDRS, n= 41) com-
pared to those receiving ESC (n= 57) (Fig. 1). Specifi-
cally, those receiving VEN had greater reductions in
psychomotor retardation at weeks 4 (t= 6.53, d.f. = 96,
P< 0.001) and 8 (t= 6.36, d.f. = 96, P< 0.001) compared
to ESC-treated participants.
Effects of psychomotor symptoms on treatment
response
Item 8 on the HDRS significantly predicted VEN but not
ESC response (Table 2). Specifically, for every one point
increase on item 8 of the HDRS we observed a 6.98 (95%
confidence interval = 1.28–37.8) increase odds of re-
sponding to 8 weeks of VEN treatment. This effect was
not found to be moderated by either of the NET
polymorphisms (P> 0.45). Neither baseline item 8 on
the HDRS or baseline CORE scale score (total score or
subscale scores) predicted antidepressant remission.
Discussion
These data indicate that psychomotor retardation symp-
toms may preferentially improve with VEN (SNRI)
compared to ESC (SSRI). This suggests that participants
Table 1 Patient characteristics stratified by antidepressant type
Full sample (n= 98) Subsample with CORE Scale (n= 51)
ESC (n= 57) VEN (n= 41) P-value ESC (n= 27) VEN (n= 24) P-value
Demographic factors
Age [mean (SD] (years) 38 (13) 41 (13) 0.29 40 (14) 44 (13) 0.36
Male [n (%)] 40 (23) 37 (15) 0.71 33 (9) 42 (10) 0.54
Caucasian [n (%)] 75 (42) 75 (30) 0.99 96 (26) 100 (24) 0.34
Tertiary education [n (%)] 61 (33) 51 (20) 0.41 55 (15) 46 (11) 0.47
Clinical factors
Baseline HDRS [mean (SD)] 23 (5) 24 (3) 0.21 24 (5) 24 (4) 0.61
Duration of depression [mean (SD)] (days) 43 (78) 38 (67) 0.73 7 (5) 6 (4) 0.61
Dose at 8 weeks [mean (SD)] (mg) 19 (8) 160 (69) – 23 (8) 175 (72) –
Baseline CORE [mean (SD)] 9 (8) 10 (7) 0.56 9 (8) 10 (7) 0.56
Baseline CGI [mean (SD)] 4 (1) 5 (1) 0.12 5 (1) 5 (1) 0.61
Treatment responders [n (%)] 74 (42) 63 (26) 0.28 70 (19) 75 (18) 0.71
Treatment remitters [n (%)] 61 (35) 56 (23) 0.60 63 (17) 63 (15) 0.97
Genotypic factors
NET rs2242446 genotype [n (%)] 0.46 0.814
CC 9 (5) 17 (7) 15 (4) 21 (5)
TC 48 (27) 42 (17) 44 (12) 38 (5)
TT 44 (25) 42 (17) 41 (11) 42 (10)
NET rs5569 genotype [n (%)] – – 0.59 – – 0.861
CC 44 (25) 37 (15) 41 (11) 33 (8)
TC 48 (27) 49 (20) 48 (13) 54 (13)
TT 9 (5) 15 (6) 11 (3) 13 (3)
CYP2C19 extensive metabolizer [n (%)] 61 (35) 61 (25) 0.96 70 (19) 75 (18) 0.64
CYP2D6 extensive metabolizer [n (%)] 60 (34) 54 (22) 0.42 67 (18) 63 (15) 0.94
5HTTLPR l carrier [n (%)] 69 (39) 63 (26) 0.45 82 (22) 83 (20) 0.75
No significant differences in demographic, clinical, or genetic features were noted for either the full sample of participants or the subgroup that had the CORE scale
administered in addition to the HDRS.
CYP2D6 metabolizer status genotyping failed for one of the ESC-treated participants.
CGI, Clinical Global Impression Scale; CORE, the Core psychomotor signs scale; ESC, escitalopram; HDRS, 17-item Hamilton Depression Rating Scale;
VEN, venlafaxine.
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with greater psychomotor symptoms (such as poor drive and
attention) could preferentially benefit from VEN and
possibly other SNRIs (Kasper, 1997). Psychomotor retarda-
tion may reflect noradrenergic dysfunction (Nutt, 2008) and
this may be concordant with our finding. This psychomotor
retardation symptom cluster has particular social and
vocational consequences in MDD, thus is an important
symptom subset of MDD to target (Dubini et al., 1997;
Kasper, 1997; Massana et al., 1999; Tse and Bond, 2002).
Should the current findings be replicated this will add
weight to the possible clinical utility of prescribers tailoring
the type of antidepressant (noradrenergic activity) to the
level of psychomotor retardation symptoms.
Response (Z 50% reduction in total HDRS score) was
not predicted by either item 8 of the HDRS or the CORE
scale at baseline, controlling for baseline severity. The
overall remission rate from MDD was not significantly
different by medication type nor predicted by baseline
psychomotor signs. Our data, however, indicate that the
psychomotor retardation symptom cluster may predict
specific antidepressant efficacy. Different types of anti-
depressant medication may have differential subsyn-
drome efficacy patterns despite no discernible
difference being present at the global syndrome level.
Several limitations of the current study must be considered
before making firm interpretation of the data. Although 113
participants were recruited, only 98 participants completed
the treatment phase of the study for analysis of the role of
item 8 and NET polymorphisms to antidepressant
response. This is a moderate sample size. Only 51
participants had a baseline CORE scale score recorded –
a small sample risking type II error. Thus, the negative
findings in this study need to be interpreted with caution.
The positive finding that VEN preferentially improves item
8 (psychomotor retardation symptoms) also needs to be
interpreted with some caution due to further limitation of
the study design and potential confounders.
Although various clinical, demographic, and genetic factors
were controlled for in this study, multiple other genetic and
environmental factors probably influence antidepressant
response. An example of this is differential childhood
trauma and recent stress levels influencing antidepressant
response, possibly mediated by epigenetic mechanisms
(Keers et al., 2011; Nanni et al., 2012). Not controlling for
this in the sample of 98 participants analyzed and other
confounders leave the data vulnerable to type I error due to
a mediating factor rather than VEN leading to the greater
reduction in psychomotor retardation symptoms. Antide-
pressant dose is also a factor to consider.
In our study, VEN was not escalated beyond 300 mg
during the 8-week treatment phase, but could be
escalated further (at clinical discretion) after the study
period. Some literature suggests patients may require up
to 450 mg for efficacy (Thase et al., 2006, Mbaya et al.,
2002). As VEN’s Ki for serotonin is much lower than for
noradrenaline (Be´ı¨que et al., 1998), it is possible
participants on lower doses of VEN had minimal
noradrenergic reuptake inhibition even at doses as high
as 300 mg/day (Debonnel et al., 2007). Extending to
treatment phase of the study to 10 or 12 weeks would
have enabled higher doses of VEN be reached and
included in the analysis.
Inclusion of participants with baseline HDRS under 25
raise issues of poorer antidepressant response rates for
antidepressants versus placebo, as participants with
baseline HDRS greater than 25 separate more robustly
from placebo on meta-analysis (Fournier et al., 2010).
However, other studies have indicated that even a HDRS
in the range 13–25 can separate from placebo with
amitriptyline (Paykel et al., 1988) but only HDRS greater
than 28 did in another study (Khan et al., 2005). We
adopted HDRS greater than 18 as a compromise between
these various findings. A more severe depressed cohort of
patients with more melancholic symptoms may have
assisted the robustness of our findings and relevance to
Fig. 1
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Percent change from baseline in psychomotor retardation (item 8
17-item Hamilton Depression Rating Scale, HDRS) for participants
completing 8 weeks of treatment (n= 98) with venlafaxine (VEN,
n= 41) or escitalopram (ESC, n= 57) adjusted for baseline HDRS
score. *Denotes significance at the P= 0.05 level. ESC, escitalopram;
VEN, venlafaxine.
Table 2 Univariate effects of HDRS item 8 and CORE score on
treatment response and remission
ESC (n= 27) VEN (n= 24)
B OR 95% CI P B OR 95% CI P
Response
Base HDRS-8 1.18 3.02 0.79–11.5 0.11 1.94 6.98 1.28–37.8 0.02
Base CORE 0.08 1.21 0.95–1.24 0.22 0.16 1.17 0.98–1.41 0.09
The CORE scale was only performed on 51 participants at one of the three study
recruitment sites.
CI, confidence interval; CORE, the Core psychomotor signs scale;
ESC, escitalopram; HDRS-8, item 8 on the Hamilton Depression Rating Scale-
17; OR, odds ratio; VEN, venlafaxine.
Bold print denotes significance at P= 0.05 level.
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more severe cases of MDD. Strengths of our study
include the prospective naturalistic blinded design,
control for potential pharmacokinetic (P450) and phar-
macodynamic (5HTTLPR) potential genetic confoun-
ders, and control for baseline HDRS and differential
antidepressant overall response rates by medication.
Other noradrenergic agents such as reboxetine may have
beneficial effects on motor function (Zittel et al., 2007)
and could also be studied for differential antidepressant
efficacy on psychomotor features of MDD to help guide
prescribers. Future studies may help shed more light on
whether VEN and other noradrenergic antidepressants
have specific efficacy for psychomotor symptoms. This is
clinically relevant given the possibility that disabling
psychomotor symptoms may preferentially respond to
noradrenergic antidepressant.
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